124 related articles for article (PubMed ID: 18618717)
1. Comparison of PAX-2, RCC antigen, and antiphosphorylated H2AX antibody (gamma-H2AX) in diagnosing metastatic renal cell carcinoma by fine-needle aspiration.
Wasco MJ; Pu RT
Diagn Cytopathol; 2008 Aug; 36(8):568-73. PubMed ID: 18618717
[TBL] [Abstract][Full Text] [Related]
2. Utility of antiphosphorylated H2AX antibody (gamma-H2AX) in diagnosing metastatic renal cell carcinoma.
Wasco MJ; Pu RT
Appl Immunohistochem Mol Morphol; 2008 Jul; 16(4):349-56. PubMed ID: 18528282
[TBL] [Abstract][Full Text] [Related]
3. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker.
Gokden N; Gokden M; Phan DC; McKenney JK
Am J Surg Pathol; 2008 Oct; 32(10):1462-7. PubMed ID: 18685487
[TBL] [Abstract][Full Text] [Related]
4. PAX-2 is a helpful marker for diagnosing metastatic renal cell carcinoma: comparison with the renal cell carcinoma marker antigen and kidney-specific cadherin.
Ozcan A; Zhai Q; Javed R; Shen SS; Coffey D; Krishnan B; Truong LD
Arch Pathol Lab Med; 2010 Aug; 134(8):1121-9. PubMed ID: 20670131
[TBL] [Abstract][Full Text] [Related]
5. The utility of Pax-2 as an immunohistochemical marker for renal cell carcinoma in cytopathology.
Gokden N; Kemp SA; Gokden M
Diagn Cytopathol; 2008 Jul; 36(7):473-7. PubMed ID: 18528893
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin.
Mentrikoski MJ; Wendroth SM; Wick MR
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):635-41. PubMed ID: 25279712
[TBL] [Abstract][Full Text] [Related]
7. Anti-alpha-inhibin: marker of choice for the consistent distinction between adrenocortical carcinoma and renal cell carcinoma in fine-needle aspiration.
Fetsch PA; Powers CN; Zakowski MF; Abati A
Cancer; 1999 Jun; 87(3):168-72. PubMed ID: 10385449
[TBL] [Abstract][Full Text] [Related]
8. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.
Ozcan A; de la Roza G; Ro JY; Shen SS; Truong LD
Arch Pathol Lab Med; 2012 Dec; 136(12):1541-51. PubMed ID: 23194047
[TBL] [Abstract][Full Text] [Related]
9. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody 'Renal Cell Carcinoma Marker'.
McGregor DK; Khurana KK; Cao C; Tsao CC; Ayala G; Krishnan B; Ro JY; Lechago J; Truong LD
Am J Surg Pathol; 2001 Dec; 25(12):1485-92. PubMed ID: 11717537
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry for the detection of renal cell carcinoma in effusion cytology.
Chute DJ; Kong CS; Stelow EB
Diagn Cytopathol; 2011 Feb; 39(2):118-23. PubMed ID: 21254459
[TBL] [Abstract][Full Text] [Related]
11. Useful immunohistochemical markers in differentiating hemangioblastoma versus metastatic renal cell carcinoma.
Rivera AL; Takei H; Zhai J; Shen SS; Ro JY; Powell SZ
Neuropathology; 2010 Dec; 30(6):580-5. PubMed ID: 20374497
[TBL] [Abstract][Full Text] [Related]
12. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms.
Avery AK; Beckstead J; Renshaw AA; Corless CL
Am J Surg Pathol; 2000 Feb; 24(2):203-10. PubMed ID: 10680888
[TBL] [Abstract][Full Text] [Related]
13. PAX-2 in the diagnosis of primary renal tumors: immunohistochemical comparison with renal cell carcinoma marker antigen and kidney-specific cadherin.
Ozcan A; Zhai J; Hamilton C; Shen SS; Ro JY; Krishnan B; Truong LD
Am J Clin Pathol; 2009 Mar; 131(3):393-404. PubMed ID: 19228645
[TBL] [Abstract][Full Text] [Related]
14. The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features.
Sharma SG; Gokden M; McKenney JK; Phan DC; Cox RM; Kelly T; Gokden N
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):494-8. PubMed ID: 21102195
[TBL] [Abstract][Full Text] [Related]
15. Multilocular cystic renal cell carcinoma: similarities and differences in immunoprofile compared with clear cell renal cell carcinoma.
Williamson SR; Halat S; Eble JN; Grignon DJ; Lopez-Beltran A; Montironi R; Tan PH; Wang M; Zhang S; Maclennan GT; Baldridge LA; Cheng L
Am J Surg Pathol; 2012 Oct; 36(10):1425-33. PubMed ID: 22982885
[TBL] [Abstract][Full Text] [Related]
16. Utility of PAX8 and PAX2 immunohistochemistry in the identification of renal cell carcinoma in diagnostic cytology.
Knoepp SM; Kunju LP; Roh MH
Diagn Cytopathol; 2012 Aug; 40(8):667-72. PubMed ID: 22807381
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of renal cell carcinoma marker in cytopathology.
Gokden N; Mukunyadzi P; James JD; Gokden M
Appl Immunohistochem Mol Morphol; 2003 Jun; 11(2):116-9. PubMed ID: 12777993
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence in situ hybridization as an adjunct tool in the diagnosis of primary and metastatic renal cell carcinoma in fine needle aspiration specimens.
Kos Z; Williams PA; Belanger EC; Mai KT
Diagn Cytopathol; 2014 Dec; 42(12):1013-23. PubMed ID: 24692327
[TBL] [Abstract][Full Text] [Related]
19. Unsuspected metastatic renal cell carcinoma diagnosed by fine needle aspiration biopsy. A report of four cases with immunocytochemical contributions.
Saleh H; Masood S; Wynn G; Assaf N
Acta Cytol; 1994; 38(4):554-61. PubMed ID: 8042422
[TBL] [Abstract][Full Text] [Related]
20. Fine-needle aspiration of metastatic clear cell carcinoma of the kidney: employment of microdissection and the polymerase chain reaction as a potential diagnostic tool.
Beaty MW; Zhuang Z; Park WS; Emmert-Buck MR; Linehan WM; Lubensky IA; Abati A
Cancer; 1997 Jun; 81(3):180-6. PubMed ID: 9196017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
